{"contentid": 488450, "importid": NaN, "name": "European seal of approval for Glenmark's innovation strategy", "introduction": "Famous as a leading Indian maker of generics, Glenmark Pharmaceuticals has taken a major step towards boosting its credentials in the innovative medicine space, with European approval for Ryaltris (olopatadine hydrochloride/mometasone furoate).", "content": "<p>Famous as a leading Indian maker of generics, Glenmark Pharmaceuticals (BSE: 532296) has taken a major step towards boosting its credentials in the innovative medicine space, with European approval for Ryaltris (olopatadine hydrochloride/mometasone furoate).</p>\n<p>The fixed-dose nasal spray is approved for the first line treatment of allergic rhinitis in people over the age of 12, and Glenmark will commercialize the product independently in select markets.</p>\n<p>Italy&rsquo;s Menarini will lead the commercialization effort in certain markets, including Italy, Spain and France, under the terms of a 2021 deal, for which Glenmark received an upfront payment and is eligible for further milestone payments.</p>\n<p>Glenmark has also partnered with Hikma Pharmaceuticals (LSE: HIK) and Bausch Health (TSX: BHC) for the commercialization of Ryaltris in the USA and Canada respectively.</p>\n<p>Ryaltris first won marketing approval in 2019, with partner Seqirus gaining the nod from Australia&rsquo;s Therapeutic Goods Administration (TGA), and has been approved in multiple other countries since, including South Korea, Russia and South Africa.</p>\n<h2>R&amp;D focus</h2>\n<p>Glenmark, a Mumbai-based company, has a long history as a developer of generic medicines for the local market and for countries around the world.</p>\n<p>Ryaltris represents the firm&rsquo;s flagship program under a strategy to invest more in R&amp;D, with the goal of building up a pipeline of innovative drugs.</p>\n<p>As part of that strategy, the firm&rsquo;s board agreed in 2019 to spin out its R&amp;D unit into an independent, fully integrated biotechnology company, dubbed Ichnos Sciences.</p>\n<p>Currently funded by Glenmark, the company launched in New Jersey, USA, with former Gilead Sciences (Nasdaq: GILD) executive Dr Alessandro Riva at the helm, and is expected to consider going public at some point.</p>\n<p>Commenting on the latest approval, regional business head Achin Gupta said: \"Despite many treatments being available for allergic rhinitis, Glenmark is excited to launch Ryaltris as the only first line combination inhaler treatment option for patients across Europe.&rdquo;</p>\n<p>He added: &ldquo;Upwards of 25% of the population in Europe suffers from the debilitating symptoms of allergic rhinitis, so we hope that Ryaltris will bring some of these real benefits - a simple inhaler, offering fast and effective relief.\"</p>", "date": "2021-04-26 10:15:00", "meta_title": NaN, "meta_keywords": "Glenmark, Ryaltris, approval, European, Pharmaceuticals, strategy, innovative, seal, innovation, Indian, maker, leading, major, step, boosting, credentials", "meta_description": "Famous as a leading Indian maker of generics, Glenmark Pharmaceuticals has taken a major step towards boosting its credentials in the innovative medicine space,", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-26 10:00:18", "updated": "2021-04-26 10:16:04", "access": NaN, "url": "https://www.thepharmaletter.com/article/european-seal-of-approval-for-glenmark-s-innovation-strategy", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "glenmark_big.jpg", "image2id": "glenmark_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Immunologicals, Respiratory and Pulmonary", "topic_tag": "Asia Pacific, European Medicines Agency, Focus On, Regulation, Research", "geography_tag": "Europe, India", "company_tag": "Glenmark Pharmaceuticals", "drug_tag": "Ryaltris", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-26 10:15:00"}